{
    "Trade/Device Name(s)": [
        "Heparin/Platelet Factor 4 Antibody Serum Panel"
    ],
    "Submitter Information": "Akers Biosciences, Inc.",
    "510(k) Number": "K052697",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983379"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGN"
    ],
    "Summary Letter Date": "January 4, 2006",
    "Summary Letter Received Date": "November 30, 2005",
    "Submission Date": "November 23, 2005",
    "Regulation Number(s)": [
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Heparin/Platelet Factor 4 Antibody"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "PIFA Heparin/Platelet Factor 4 Antibody Assay systems",
        "GTI PF4 ENHANCED ELISA Assay"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Rapid assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Panel"
    ],
    "Document Summary": "FDA 510(k) summary for Heparin/Platelet Factor 4 Antibody Serum Panel, a serum QC control for monitoring and evaluating PIFA Heparin PF4 Antibody Assay systems.",
    "Indications for Use Summary": "Assayed control intended for use as a serum QC control to monitor and evaluate precision and accuracy of the (qualitative) PIFA Heparin PF4 Antibody Assay, including both confirmed positive and negative control panel members.",
    "fda_folder": "Hematology"
}